Conclusion: QLFTs independently predict risk for future clinical outcomes. By improving risk assessment, QLFTs could enhance the noninvasive monitoring, counseling, AZD4547 and management of patients with chronic HCV. (HEPATOLOGY 2012) Chronic hepatitis C virus (HCV) is a major cause of liver disease, cirrhosis, and hepatocellular carcinoma (HCC) in the United States and worldwide.1-4 Early detection of patients with significant hepatic impairment, who are at risk for future decompensation, is a priority of clinical management. Progression of liver disease is defined histologically by accumulation of fibrosis and physiologically by impairment
of hepatic function and blood flow. Increased Ishak fibrosis score5, 6 or increased hepatic venous pressure gradient (HVPG)7-9 indicate greater severity of liver disease and identify patients
at risk for future clinical complications. Quantifying fibrosis requires the performance of liver biopsy, and measuring HVPG is technically complex and requires catheterization of the jugular vein. Both liver biopsy and HVPG measurement AZD2014 order are associated with potentially severe complications, prone to sampling error, and may not be embraced by patients. Accurate noninvasive methods for staging of disease are needed. One noninvasive approach is to develop models based on clinical findings and standard blood tests. Child-Turcotte-Pugh (CTP) classification10 and model for end-stage liver disease (MELD) score11, 12 are, perhaps, the best known and most commonly applied. Both were developed to predict surgical mortality or mortality after transjugular intrahepatic portal-systemic shunt (TIPS) in patients with advanced cirrhosis. Neither are applicable to the patient with earlier-stage or clinically compensated disease.13 Other models target patients with compensated this website disease. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial investigators developed a model based upon bilirubin, albumin, aspartate aminotransferase/alanine aminotransferase (AST/ALT), and platelet count.14
This model identified high-risk patients, 59% of whom developed clinical outcomes in 3.5 years of follow-up. But, the high-risk cutoff was insensitive; only 46% of the patients who eventually developed outcomes were identified. Hepatic elastography and serum fibrosis markers correlate with stage of fibrosis, as well as risk for cirrhosis or varices.15-18 In one study, hyaluronic acid, YKL-40, and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), combined with standard laboratory tests, were significantly associated with disease progression.18 Further studies of elastography and serum fibrosis markers in predicting future risk for clinical outcomes are needed to validate their prognostic value.